These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25826594)

  • 1. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.
    Barry PJ; Ronan N; Plant BJ
    Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy in cystic fibrosis.
    Prickett M; Jain M
    Transl Res; 2013 Apr; 161(4):255-64. PubMed ID: 23273902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medicine in cystic fibrosis: dawning of a new era.
    Clancy JP; Jain M
    Am J Respir Crit Care Med; 2012 Oct; 186(7):593-7. PubMed ID: 22723294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.
    Merk D; Schubert-Zsilavecz M
    Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Root Cause of Cystic Fibrosis.
    Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
    Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular repair of a defective CFTR protein in cystic fibrosis.
    Erlinger S
    Clin Res Hepatol Gastroenterol; 2011 Apr; 35(4):254-6. PubMed ID: 21349786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the diagnosis and treatment of cystic fibrosis.
    Martiniano SL; Hoppe JE; Sagel SD; Zemanick ET
    Adv Pediatr; 2014 Aug; 61(1):225-43. PubMed ID: 25037130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.